Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti‐hyperglycemic drugs

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1557|1053-8569|10|1017-1025

ISSN： 1053-8569

Source： PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol.1053-8569, Iss.10, 2015-10, pp. : 1017-1025

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti‐hyperglycemic drugs

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 24, Iss. 10, 2015-10 ,pp. : 1017-1025

John Wiley & Sons Inc

Access to resources Recommend Favorite

DPP‐4i, SU, and β‐cell function

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 2, 2015-03 ,pp. : 213-221

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dipeptidyl peptidase‐4 inhibitors moderate the risk of genitourinary tract infections associated with sodium‐glucose co‐transporter‐2 inhibitors

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 740-744

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP‐4 inhibitors with other oral antidiabetic drugs

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 430-434

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dipeptidyl peptidase‐4 inhibitors and the risk of community‐acquired pneumonia in patients with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 379-385

John Wiley & Sons Inc

Access to resources Recommend Favorite